TY - JOUR
T1 - Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology
T2 - Cellular and Molecular Mechanisms
AU - Xiao, Lei
AU - Nie, Xin
AU - Cheng, Yanyan
AU - Wang, Nanping
N1 - Publisher Copyright:
© 2021, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/12
Y1 - 2021/12
N2 - Sodium-glucose cotransporter-2 (SGLT2) inhibitors are new antidiabetic drugs that reduce hyperglycemia by inhibiting the glucose reabsorption in renal proximal tubules. Clinical studies have shown that SGLT2 inhibitors not only improve glycemic control but also reduce major adverse cardiovascular events (MACE, cardiovascular and total mortality, fatal or nonfatal myocardial infarction or stroke) and hospitalization for heart failure (HF), and improve outcome in chronic kidney disease. These cardiovascular and renal benefits have now been confirmed in both diabetes and non-diabetes patients. The precise mechanism(s) responsible for the protective effects are under intensive investigation. This review examines current evidence on the cardiovascular benefits of SGLT2 inhibitors, with a special emphasis on the vascular actions and their potential mechanisms.
AB - Sodium-glucose cotransporter-2 (SGLT2) inhibitors are new antidiabetic drugs that reduce hyperglycemia by inhibiting the glucose reabsorption in renal proximal tubules. Clinical studies have shown that SGLT2 inhibitors not only improve glycemic control but also reduce major adverse cardiovascular events (MACE, cardiovascular and total mortality, fatal or nonfatal myocardial infarction or stroke) and hospitalization for heart failure (HF), and improve outcome in chronic kidney disease. These cardiovascular and renal benefits have now been confirmed in both diabetes and non-diabetes patients. The precise mechanism(s) responsible for the protective effects are under intensive investigation. This review examines current evidence on the cardiovascular benefits of SGLT2 inhibitors, with a special emphasis on the vascular actions and their potential mechanisms.
KW - Mechanisms
KW - Pharmacology
KW - Sodium-glucose cotransporter-2 inhibitor
KW - Type 2 diabetes mellitus
KW - Vascular biology
UR - https://www.scopus.com/pages/publications/85110663053
U2 - 10.1007/s10557-021-07216-9
DO - 10.1007/s10557-021-07216-9
M3 - 文献综述
C2 - 34273091
AN - SCOPUS:85110663053
SN - 0920-3206
VL - 35
SP - 1253
EP - 1267
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 6
ER -
